NCT07810777RecruitingPhase 2
PRA-216 Atopic Dermatitis Safety and Efficacy Study
A Phase 2 Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Multi-Center Study to Evaluate the Safety and Efficacy of PRA-216 in Participants With Moderate to Severe Atopic Dermatitis
Source: ClinicalTrials.gov · Last updated 28 Oct 2026
Brief summary (registry, in English)
This study will evaluate the safety, tolerability, pharmacokinetics and immunogenicity of PRA-216 compared to placebo in patients with moderate to severe Atopic Dermatitis (AD)
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 39 (estimated)
- First submitted
- 3 Sept 2026
- Start date
- 17 Sept 2026
- Primary completion date
- 30 Sept 2027
- Lead sponsor
- Prana Therapies Inc
- Diseases
- Atopic dermatitis (eczema)
- NCT number
- NCT07810777
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 39
- From 17 Sept 2026 to the primary completion date, 30 Sept 2027
- 9 sites in 2 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Known history of illicit drug use or alcoholism within 12 months prior to the first dose of study agent
- Receipt of antibody therapy within 4 months or 5 half-lives
- Other investigational agent(s) within 30 days or 5 half-lives
Other illness
- Evidence of clinically significant skin condition or disease other than AD
- Any physical or psychological condition that prohibits study completion
- History of severe allergic reactions or hypersensitivity
Who the study is looking for
- Must be in good health with no significant medical history
- Willing and able to attend all study visits, comply with study requirements.
- Able and willing to provide written informed consent
- Documented AD diagnosis prior to enrollment.
- History of inadequate response to topical medications for AD
Age in the registry: 18 years to 70 years · Sex: All · Does not accept healthy volunteers
Sites (9)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Emeritus - Sydney Coordinator of this site? Confirm its status | Botany | Australia | Recruiting |
| Emeritus - Melbourne Coordinator of this site? Confirm its status | Camberwell | Australia | Not yet recruiting |
| Cornerstone Centre for Clinical Research Coordinator of this site? Confirm its status | Coorparoo | Australia | Recruiting |
| Aperio Clinical Research Coordinator of this site? Confirm its status | Liverpool | Australia | Not yet recruiting |
| Momentum Sunshine Coordinator of this site? Confirm its status | Melbourne | Australia | Not yet recruiting |
| Optimal Clinical Trials (North) Coordinator of this site? Confirm its status | Auckland | New Zealand | Recruiting |
| Aotearoa Clinical Trials Coordinator of this site? Confirm its status | Auckland | New Zealand | Recruiting |
| Momentum Christchurch Coordinator of this site? Confirm its status | Christchurch | New Zealand | Recruiting |
| Clinical Trials New Zealand Coordinator of this site? Confirm its status | Hamilton | New Zealand | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.